DDX5 and psoriasis: In conclusion, our observations indicate that the IL-17D–CD93-mediated decrease in DDX5 expression amplifies cutaneous inflammation and suggest a potential for IL-17D and DDX5 as therapeutic targets in inflammatory skin diseases, whereas the identification of sIL-36R provides insights into the contribution of aberrant RNA splicing to skin inflammation, and may ultimately lead to the development of alternative therapeutic approaches in AD and psoriasis.